Revolution of Drug-Eluting Coronary Stents: An Analysis of Market Leaders - European Medical Journal


Revolution of Drug-Eluting Coronary Stents: An Analysis of Market Leaders

| Download as | PDF
*Ashok S. Thakkar,1 Bhargav A. Dave2,3

Ashok S. Thakkar is an employee of Meril Life Science Pvt., Ltd. Bhargav A. Dave has declared no conflicts of interest.

EMJ. ;1[4]:114-125.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Percutaneous coronary intervention with drug-eluting stents (DES) is a well-established and widely-accepted treatment approach in patients with coronary artery disease. Although the underlying principle of DES remains constant for different stents available on the market, certain factors may offer variations with respect to deliverability (ease of placement), efficacy (preventing restenosis), and safety (thrombosis rates). These factors may include the type of drug (sirolimus, everolimus, biolimus, zotarolimus, novolimus, paclitaxel, docetaxel), type of stent platforms (stainless steel, platinum, cobalt-chromium, cobalt-nickel, platinum-chromium), type of polymers (permanent, biodegradable, polymer-free), thickness of stent struts (thick, thin, ultra-thin), type of coating (abluminal, conformal), and type of stent design (open-cell, closed-cell, combination of open-closed cell). In this context, we present a review on characteristic features of several of the most widely used coronary stents worldwide. Furthermore, the advancements of completely biodegradable stents are discussed. In addition, the future directions for the development of creating an ideal or perfect DES are debated.

Please view the full content in the pdf above.